The use of engineered probiotics to deliver cytokines, such as interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF), has gained significant attention in recent years as a promising approach in cancer immunotherapy. This evidence concerns the gene CSF2 and cancer.